drugset / Trial / NCT03172819
Special Combination of OBP-301 and Pembrolizumab
Phase 1
Completed
22 enrolled
Toshihiko Doi
Merck Sharp & Dohme LLC · collabOncolys BioPharma Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.
Timeline
- Start
- 2017-10-01
- Primary completion
- 2021-04-06
- Completion
- 2022-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | suratadenoturev | Unknown | — | Other |